| Company Name: |
BOC Sciences
|
| Tel: |
|
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:TPC-144
CAS:2098621-17-9
Remarks:TPC-144 is a novel and selective LSD1 inhibitor potentially used for the treatment of acute myeloid leukemia (AML) and small cell lung cancer (SCLC). TPC-144 reversibly inhibited LSD1 in a histone pep
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:TPC-144
CAS:2098621-17-9
Purity:98% Package:5 mg
|
|
| | TPC-144 Basic information |
| Product Name: | TPC-144 | | Synonyms: | TPC-144;[1,1':2',1''-Terphenyl]-4-carbonitrile, 5'-[[(3-endo)-3-amino-8-azabicyclo[3.2.1]oct-8-yl]carbonyl]-2'',3-difluoro-4''-(2-hydroxy-2-methylpropyl)- | | CAS: | 2098621-17-9 | | MF: | C31H31F2N3O2 | | MW: | 515.6 | | EINECS: | | | Product Categories: | | | Mol File: | 2098621-17-9.mol |  |
| | TPC-144 Chemical Properties |
| Boiling point | 665.5±55.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | pka | 14.25±0.29(Predicted) |
| | TPC-144 Usage And Synthesis |
| Description | TPC-144 is a novel, potent and selective LSD1 inhibitor with a reversible inhibition mechanism that has antitumor activity in several human AML and SCLC cell lines and xenograft models. TPC-144 may provide clinical benefits and a favorable safety profile for the treatment of AML and SCLC patients. TPC-144 reversibly inhibited LSD1 in a histone peptide-competitive manner and did not form a covalent adduct with FAD. TPC-144 inhibited LSD1 with an IC50 of 1.5?nM and had selectivity over other histone demethylases and methyltransferases. TPC-144 induced cell differentiation, as indicated by derepression of hematopoietic transcription factor GFI1; increased expression of cell-surface markers such as CD86 and CD11b, and potently inhibited growth of AML cells (e.g., Kasumi-1, IC50?=?1.3?nM; MV4–11, IC50?=?2.4?nM; HEL, IC50?=?7.1?nM) by inducing apoptosis and cell cycle arrest. |
| | TPC-144 Preparation Products And Raw materials |
|